drugset / Trial / NCT03430518
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the recommended Phase 2 combination dose (RP2D) of eribulin with durvalumab.
Timeline
- Start
- 2018-05-17
- Primary completion
- 2020-02-10
- Completion
- 2020-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1.12 g | Intravenous |
| Subject | Eribulin | Small molecule | 0.7 mg/m2 | Intravenous |
| Subject | Eribulin | Small molecule | 1.1 mg/m2 | Intravenous |
| Subject | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |